Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review

Ähnliche Einträge

• Artificial intelligence in the diagnosis of gastro‐entero‐pancreatic neuroendocrine neoplasms: Potential benefits and current limitations
  von: Elettra Merola, et al.
  Veröffentlicht: (2025)
• Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
  von: Jelka Kuiper, et al.
  Veröffentlicht: (2024)
• Controversies in neuroendocrine neoplasms: An European Neuroendocrine Tumor Society position statement on the role of surgery of the primary tumour in metastatic small intestinal and pancreatic neuroendocrine tumours
  von: Stefano Partelli, et al.
  Veröffentlicht: (2026)
• Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors
  von: Giulia Santo, et al.
  Veröffentlicht: (2025)
• The impact of re‐characterizing metastatic pancreatic neuroendocrine tumors: A prospective study
  von: Kazhan Mollazadegan, et al.
  Veröffentlicht: (2025)